Opus Genetics Statistics
Total Valuation
Opus Genetics has a market cap or net worth of $45.19 million. The enterprise value is $9.18 million.
Important Dates
The next confirmed earnings date is Monday, March 31, 2025, before market open.
Earnings Date | Mar 31, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Opus Genetics has 44.96 million shares outstanding. The number of shares has increased by 14.60% in one year.
Current Share Class | 44.96M |
Shares Outstanding | 44.96M |
Shares Change (YoY) | +14.60% |
Shares Change (QoQ) | +1.23% |
Owned by Insiders (%) | 5.07% |
Owned by Institutions (%) | 8.17% |
Float | 40.12M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 3.00 |
Forward PS | 3.78 |
PB Ratio | 0.77 |
P/TBV Ratio | 1.34 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 1.10 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.63
Current Ratio | 6.63 |
Quick Ratio | 6.56 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -22.19 |
Financial Efficiency
Return on equity (ROE) is -64.30% and return on invested capital (ROIC) is -43.56%.
Return on Equity (ROE) | -64.30% |
Return on Assets (ROA) | -38.95% |
Return on Invested Capital (ROIC) | -43.56% |
Return on Capital Employed (ROCE) | -85.93% |
Revenue Per Employee | $598,643 |
Profits Per Employee | -$1.94M |
Employee Count | 14 |
Asset Turnover | 0.18 |
Inventory Turnover | n/a |
Taxes
Income Tax | -2,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.30% in the last 52 weeks. The beta is 0.25, so Opus Genetics's price volatility has been lower than the market average.
Beta (5Y) | 0.25 |
52-Week Price Change | -49.30% |
50-Day Moving Average | 1.08 |
200-Day Moving Average | 1.29 |
Relative Strength Index (RSI) | 46.34 |
Average Volume (20 Days) | 272,015 |
Short Selling Information
The latest short interest is 685,446, so 1.52% of the outstanding shares have been sold short.
Short Interest | 685,446 |
Short Previous Month | 703,397 |
Short % of Shares Out | 1.52% |
Short % of Float | 1.71% |
Short Ratio (days to cover) | 3.44 |
Income Statement
In the last 12 months, Opus Genetics had revenue of $8.38 million and -$27.19 million in losses. Loss per share was -$1.09.
Revenue | 8.38M |
Gross Profit | -15.39M |
Operating Income | -29.47M |
Pretax Income | n/a |
Net Income | -27.19M |
EBITDA | -29.47M |
EBIT | -29.47M |
Loss Per Share | -$1.09 |
Full Income Statement Balance Sheet
The company has $36.64 million in cash and n/a in debt, giving a net cash position of $36.64 million or $0.81 per share.
Cash & Cash Equivalents | 36.64M |
Total Debt | n/a |
Net Cash | 36.64M |
Net Cash Per Share | $0.81 |
Equity (Book Value) | 34.30M |
Book Value Per Share | 1.31 |
Working Capital | 34.30M |
Full Balance Sheet Cash Flow
Operating Cash Flow | -13.59M |
Capital Expenditures | n/a |
Free Cash Flow | -13.59M |
FCF Per Share | -$0.30 |
Full Cash Flow Statement Margins
Gross Margin | -183.63% |
Operating Margin | -351.68% |
Pretax Margin | -324.47% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Opus Genetics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -14.60% |
Shareholder Yield | -14.60% |
Earnings Yield | -59.35% |
FCF Yield | -29.66% |
Analyst Forecast
The average price target for Opus Genetics is $8.00, which is 696.02% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $8.00 |
Price Target Difference | 696.02% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | 20.17% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Opus Genetics has an Altman Z-Score of 0.37 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 0.37 |
Piotroski F-Score | 1 |